Certara (NASDAQ:CERT) Trading Up 7.4% – Here’s What Happened

Certara, Inc. (NASDAQ:CERT)’s stock price traded up 7.4% on Wednesday . The stock traded as high as $13.14 and last traded at $13.55. 73,853 shares were traded during trading, a decline of 92% from the average session volume of 953,037 shares. The stock had previously closed at $12.61.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of research analyst reports. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Robert W. Baird decreased their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Finally, Barclays cut their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.92.

Certara Stock Up 1.7 %

The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s fifty day moving average price is $11.06 and its 200 day moving average price is $11.90.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter last year, the company earned $0.06 earnings per share. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Institutional Trading of Certara

A number of large investors have recently bought and sold shares of the stock. Blue Trust Inc. boosted its stake in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Certara by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock valued at $317,000 after buying an additional 975 shares in the last quarter. Nicolet Advisory Services LLC grew its stake in Certara by 6.6% during the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock worth $273,000 after buying an additional 1,531 shares during the last quarter. KBC Group NV increased its holdings in shares of Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares in the last quarter. Finally, Everence Capital Management Inc. raised its stake in shares of Certara by 21.0% in the third quarter. Everence Capital Management Inc. now owns 14,910 shares of the company’s stock valued at $175,000 after acquiring an additional 2,590 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.